Delivery Order SPE2DB20D3103-SPE2DB25FN9Y9
- Not listed
- The Defense Logistics Agency awarded a $4,481.35 delivery order to AmerisourceBergen Drug Corp for 500 mg Dalvance vials on April 22, 2025, with a completion date of April 23, 2025. This non-competitive delivery order utilizes firm fixed pricing and is being performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with the DLA. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $18,608.38 delivery order to AmerisourceBergen Drug Corp for 500 mg Dalvance vials, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price contract was issued with no set-aside designation. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement valued through December 2026 that...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency for 500 mg vials of Dalvance (dalbavancin), a broad-spectrum antibiotic, with a ceiling value of $3,658.32. The contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and was awarded on August 4, 2025. This award carries no set-aside designation, indicating it was competitively awarded through open competition. The place of performance is AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 2, 2025, for the supply of Dalvance 500 mg vials with a contract ceiling value of $3,647.09. This is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and was funded through the Defense Logistics Agency's Medical Supply Chain. The award was made through competitive procurement with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order valued at $10,284.07 to AmerisourceBergen Drug Corp for 500 mg vials of Dalvance, a broad-spectrum antibiotic commonly used in military and federal healthcare settings. This firm fixed-price delivery order was competitively awarded without set-aside provisions and is scheduled for completion by August 15, 2025. The award represents a single transaction under AmerisourceBergen's larger contract vehicle with DLA Troop Support Medical. This...
- The Defense Logistics Agency awarded a $16,882.84 delivery order to AmerisourceBergen Drug Corp for the supply of Dalvance 500 mg vials, with an ultimate completion date of June 26, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement typical of the agency's pharmaceutical procurement operations. The award leverages AmerisourceBergen's established position as a critical federal medical vendor, particularly within the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a $5,961.05 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dalvance 500 mg vials, with an ultimate completion date of September 10, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order valued at $5,377.68 to AmerisourceBergen Drug Corp for the supply of Dalvance 500 mg vials, an antibiotic medication used to treat bacterial skin infections. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a non-competitive, non-set-aside purchase. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $3,760.90 delivery order to AmerisourceBergen Drug Corp for 500 mg vials of Dalvance, an antibiotic pharmaceutical product. This competitively awarded, firm fixed-price contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child delivery order, this award falls under the company's larger...
- The Defense Logistics Agency awarded a $2,688.81 delivery order to AmerisourceBergen Drug Corp for 500 mg vials of Dalvance, a specialty antibiotic used to treat bacterial skin infections. This firm fixed price delivery order, awarded on May 30, 2025, with completion expected by June 2, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical supply...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FN9Y9Delivery Order
The Defense Logistics Agency awarded a $4,481.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 500 mg Dalvance vials, with an ultimate completion date of May 30, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dalvance (dalbavancin) is an antibiotic used in the treatment of bacterial skin infections and is part of the Defense Health Agency's pharmaceutical support requirements for military healthcare systems. This award reflects AmerisourceBergen's role as a critical pharmaceutical distributor serving federal medical procurement needs through the DLA's comprehensive global pharmaceutical support vehicle, which enables supply of medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The contract demonstrates the company's capacity to fulfill federal medical supply needs through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 5/29/25 |